Narayana Health has reported strong financial results for the fiscal year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹81,344.74 million and a profit after tax of ₹8,059.79 million. Reflecting this robust performance, the Board of Directors has recommended a final dividend of ₹4.50 per share. The company also announced plans to raise funds for debt securities and confirmed the re-appointment of an Independent Director.
Annual Financial Performance
For the fiscal year ending March 31, 2026, Narayana Health delivered consistent growth. The company reported a consolidated annual revenue of ₹81,344.74 million, showcasing its operational scale. Net profit for the same period stood at ₹8,059.79 million, underscoring the firm’s profitability and financial resilience. The standalone results were equally solid, with an annual revenue of ₹41,515.75 million and a net profit of ₹5,031.13 million.
Shareholder Returns and Corporate Governance
The Board of Directors has recommended a final dividend of ₹4.50 per share for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming 26th Annual General Meeting scheduled for August 14, 2026. The record date to identify eligible shareholders for this dividend payout has been set for July 17, 2026.
In addition to financial distribution, the company continues to strengthen its leadership team. The board has approved the re-appointment of Ms. Terri Smith Bresenham as an Independent Director for a second five-year term, effective August 5, 2026, through August 4, 2031.
Strategic Growth and Funding Initiatives
To support ongoing strategic objectives and capital requirements, the company has secured enabling approval to issue debt securities, including Non-Convertible Debentures (NCDs), up to an aggregate amount of ₹1,500 crore in a financial year on a private placement basis. This move is intended to provide the necessary flexibility to manage the company’s capital structure and fund future expansion efforts effectively.
Source: BSE
